Zhejiang Hisun Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 600267.SS

Zhejiang Hisun Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2023: USD 1.46 B

Zhejiang Hisun Pharmaceutical Co., Ltd. Revenue is USD 1.46 B for the year ending December 31, 2023, a -16.24% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Zhejiang Hisun Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2022 was USD 1.74 B, a -8.68% change year over year.
Zhejiang Hisun Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2021 was USD 1.91 B, a 9.80% change year over year.
Zhejiang Hisun Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2020 was USD 1.74 B, a 9.41% change year over year.
Zhejiang Hisun Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2019 was USD 1.59 B, a 7.34% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 600267.SS

Zhejiang Hisun Pharmaceutical Co., Ltd.

CEO	Mr. Weihong Xiao
IPO Date	July 25, 2000
Location	China
Headquarters	No. 46, Waisha Road
Employees	8,062
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Drugstores & Retail Pharmacies Personal Care Pet Food

Description

Zhejiang Hisun Pharmaceutical Co., Ltd. manufactures and supplies pharmaceutical products in China. It provides active pharmaceutical ingredients and finished dosage form products. The company offers products in the areas of anti-tumor, cardiovascular, anti-infective, liver care, orthopedics, anticancer, anti-parasitic, immunosuppressant, etc.; and weight loss, anti-viral, anti-TB, veterinary pharma, and others. It also provides product consultation and CMO/CRO manufacturing services. The company was founded in 1956 and is headquartered in Taizhou, China.

Key trends

Past 5 years